TOMI Environmental Solutions, Inc.: management transactions · United States · SEC (Form 4)

About TOMI Environmental Solutions, Inc.

TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) is a U.S.-listed company traded on the NASDAQ market in the United States, focused on disinfection, decontamination, and infection-prevention solutions. Headquartered in Frederick, Maryland, the company operates in a specialized niche at the intersection of healthcare, industrial hygiene, and controlled environments. For investors, TOMI is best viewed as a thematic small-cap exposure to structural demand for biosecurity in hospitals, laboratories, cleanrooms, pharmaceutical manufacturing sites, transportation assets, and public facilities. ([investor.tomimist.com](https://investor.tomimist.com/?utm_source=openai)) The company’s core business is built around its proprietary Binary Ionization Technology® (BIT™), marketed under the SteraMist® brand. TOMI describes BIT as a hydrogen-peroxide-based platform designed for indoor surface decontamination and pathogen reduction in sensitive environments. Its commercial model combines manufacturing, direct sales, licensing, and related services. The portfolio includes equipment systems, Custom Engineered Systems (CES), hybrid solutions, and iHP decontamination services. TOMI states that its products serve a broad customer base including hospitals, medical facilities, biosafety labs, cleanrooms, pharmaceutical manufacturers, cruise ships, schools, restaurants, and military facilities. ([investor.tomimist.com](https://investor.tomimist.com/?utm_source=openai)) Historically, TOMI has developed around a proprietary technology platform and a licensing-oriented commercialization strategy. Its competitive position is driven less by scale than by specialization, differentiated technology, and the ability to address use cases where decontamination performance is mission-critical. The company also emphasizes an international footprint and ongoing commercial expansion, with a particular focus on life sciences, healthcare, and pharmaceutical manufacturing. ([investor.tomimist.com](https://investor.tomimist.com/?utm_source=openai)) Recent developments suggest an active transformation phase. In 2025 and 2026, TOMI reported improving quarterly trends, higher revenue, and a larger set of commercial opportunities. In March 2026, the company released full-year 2025 results and highlighted growth initiatives, including continued R&D investment to broaden SteraMist applications across life sciences, food safety, and commercial markets. In April 2026, TOMI announced a transformative letter of intent to merge with Carbonium Core, Inc., while also communicating more aggressive positioning around defense-related and autonomous decontamination applications. Taken together, these updates indicate a company still dependent on a relatively narrow product base, but actively working to expand recurring revenue, deepen customer adoption, and widen its end-market reach. ([nasdaq.com](https://www.nasdaq.com/press-release/tomi-environmental-solutions-inc-reports-full-year-2025-financial-results-and?utm_source=openai))